BRAIN Biotech AG (BNN.DE)

EUR 3.77

(-3.58%)

Total Liabilities Summary of BRAIN Biotech AG

BRAIN Biotech AG's latest annual total liabilities in 2023 was 47.92 Million EUR , up 9.55% from previous year.
BRAIN Biotech AG's latest quarterly total liabilities in 2024 Q3 was 56.58 Million EUR , up 5.49% from previous quarter.
BRAIN Biotech AG reported annual total liabilities of 43.74 Million EUR in 2022, up 21.82% from previous year.
BRAIN Biotech AG reported annual total liabilities of 35.91 Million EUR in 2021, down -21.95% from previous year.
BRAIN Biotech AG reported quarterly total liabilities of 45.98 Million EUR for 2024 Q1, down -4.04% from previous quarter.
BRAIN Biotech AG reported quarterly total liabilities of 56.58 Million EUR for 2024 Q3, up 5.49% from previous quarter.

Annual Total Liabilities Chart of BRAIN Biotech AG (2023 - 2012)

Historical Annual Total Liabilities of BRAIN Biotech AG (2023 - 2012)

Year	Total Liabilities	Total Liabilities Growth
2023	47.92 Million EUR	9.55%
2022	43.74 Million EUR	21.82%
2021	35.91 Million EUR	-21.95%
2020	46 Million EUR	-6.17%
2019	49.03 Million EUR	11.88%
2018	43.82 Million EUR	107.29%
2017	21.14 Million EUR	2.7%
2016	20.58 Million EUR	-16.49%
2015	24.65 Million EUR	119.64%
2014	11.22 Million EUR	49.55%
2013	7.5 Million EUR	-1.08%
2012	7.58 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	53.64 Million EUR	16.65%
2024 Q1	45.98 Million EUR	-4.04%
2024 Q3	56.58 Million EUR	5.49%
2023 Q3	44.88 Million EUR	0.55%
2023 Q4	47.92 Million EUR	6.76%
2023 FY	47.92 Million EUR	9.55%
2023 Q1	43.83 Million EUR	0.22%
2023 Q2	44.64 Million EUR	1.84%
2022 Q3	45.22 Million EUR	-2.56%
2022 Q2	46.41 Million EUR	28.4%
2022 Q1	36.14 Million EUR	0.66%
2022 FY	43.74 Million EUR	21.82%
2022 Q4	43.74 Million EUR	-3.27%
2021 FY	35.91 Million EUR	-21.95%
2021 Q2	41.13 Million EUR	-7.06%
2021 Q3	35.94 Million EUR	-12.61%
2021 Q4	35.91 Million EUR	-0.1%
2021 Q1	44.26 Million EUR	-3.79%
2020 Q2	51.92 Million EUR	-5.9%
2020 Q3	49.82 Million EUR	-4.04%
2020 Q4	46 Million EUR	-7.67%
2020 FY	46 Million EUR	-6.17%
2020 Q1	55.18 Million EUR	12.54%
2019 Q3	42.32 Million EUR	-1.45%
2019 FY	49.03 Million EUR	11.88%
2019 Q4	49.03 Million EUR	15.85%
2019 Q2	42.94 Million EUR	-0.74%
2019 Q1	43.26 Million EUR	-1.27%
2018 Q3	46.15 Million EUR	15.47%
2018 Q4	43.82 Million EUR	-5.04%
2018 FY	43.82 Million EUR	107.29%
2018 Q1	21.25 Million EUR	0.53%
2018 Q2	39.97 Million EUR	88.06%
2017 FY	21.14 Million EUR	2.7%
2017 Q1	21.41 Million EUR	4.05%
2017 Q2	20.37 Million EUR	-4.88%
2017 Q3	19.69 Million EUR	-3.33%
2017 Q4	21.14 Million EUR	7.35%
2016 FY	20.58 Million EUR	-16.49%
2016 Q4	20.58 Million EUR	9.71%
2016 Q2	18.86 Million EUR	-24.6%
2016 Q1	25.01 Million EUR	1.49%
2016 Q3	18.76 Million EUR	-0.54%
2015 Q4	24.65 Million EUR	0.0%
2015 Q1	- EUR	0.0%
2015 FY	24.65 Million EUR	119.64%
2014 FY	11.22 Million EUR	49.55%
2013 FY	7.5 Million EUR	-1.08%
2012 FY	7.58 Million EUR	0.0%

Peer Total Liabilities Comparison of BRAIN Biotech AG

Name	Total Liabilities	Total Liabilities Difference
BioNTech SE	2.76 Billion EUR	98.264%
CureVac N.V.	271.53 Million EUR	82.351%
Biotest Aktiengesellschaft	945.4 Million EUR	94.931%
Biotest Aktiengesellschaft	945.4 Million EUR	94.931%
Formycon AG	387.61 Million EUR	87.636%
Heidelberg Pharma AG	21.01 Million EUR	-128.061%
Medigene AG	10.65 Million EUR	-349.981%